128 related articles for article (PubMed ID: 33858766)
1. Eribulin in combination with HER2-targeted antibodies for successful treatment of metastatic salivary duct carcinoma: A report of two cases.
Fujimi A; Nagamachi Y; Yamauchi N; Nishisato T; Murase K; Takada K; Tsujiwaki M; Sugita S; Hasegawa T; Kato J
Oral Oncol; 2021 Sep; 120():105287. PubMed ID: 33858766
[No Abstract] [Full Text] [Related]
2. Exceptional responses to pertuzumab, trastuzumab, and docetaxel in human epidermal growth factor receptor-2 high expressing salivary duct carcinomas.
Park JC; Ma TM; Rooper L; Hembrough T; Foss RD; Schmitt NC; Sawhney R; Flanders A; Kang H
Head Neck; 2018 Dec; 40(12):E100-E106. PubMed ID: 30478962
[TBL] [Abstract][Full Text] [Related]
3. [A case of metastatic salivary duct carcinoma successfully treated with trastuzumab-based targeted therapy].
Iguchi F; Taniguchi Z; Kusano J; Takahashi Y; Murai N
Nihon Jibiinkoka Gakkai Kaiho; 2014 Aug; 117(8):1108-14. PubMed ID: 25255650
[TBL] [Abstract][Full Text] [Related]
4. Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD).
Yamashita T; Masuda N; Saji S; Araki K; Ito Y; Takano T; Takahashi M; Tsurutani J; Koizumi K; Kitada M; Kojima Y; Sagara Y; Tada H; Iwasa T; Kadoya T; Iwatani T; Hasegawa H; Morita S; Ohno S
Trials; 2020 May; 21(1):391. PubMed ID: 32381018
[TBL] [Abstract][Full Text] [Related]
5. Significant and durable clinical benefit from trastuzumab in 2 patients with HER2-amplified salivary gland cancer and a review of the literature.
Thorpe LM; Schrock AB; Erlich RL; Miller VA; Knost J; Le-Lindqwister N; Jujjavarapu S; Ali SM; Liu JJ
Head Neck; 2017 Mar; 39(3):E40-E44. PubMed ID: 28006087
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of the eribulin, pertuzumab, and trastuzumab combination therapy for human epidermal growth factor receptor 2-positive advanced or metastatic breast cancer: a multicenter, single arm, phase II study (JBCRG-M03 study).
Yamashita T; Kawaguchi H; Masuda N; Kitada M; Narui K; Hattori M; Yoshinami T; Matsunami N; Yanagihara K; Kawasoe T; Nagashima T; Bando H; Yano H; Hasegawa Y; Nakamura R; Kashiwaba M; Morita S; Ohno S; Toi M
Invest New Drugs; 2021 Feb; 39(1):217-225. PubMed ID: 32833136
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of eribulin mesylate in recurrent or metastatic salivary gland malignancies.
Rodriguez CP; Martins RG; Baik C; Chow LQ; Santana-Davila R; Goulart BH; Lee S; Eaton KD
Head Neck; 2018 Mar; 40(3):584-589. PubMed ID: 29283469
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety evaluation of eribulin-trastuzumab combination therapy with heavily pretreated HER2-positive metastatic breast cancer.
Sarici F; Altundag K
J BUON; 2020; 25(6):2562-2569. PubMed ID: 33455097
[TBL] [Abstract][Full Text] [Related]
9. Combination Chemohormonal Therapy in Metastatic Salivary Duct Carcinoma.
Jeong ISD; Moyers J; Thung I; Thinn MM
Am J Case Rep; 2020 Jun; 21():e925181. PubMed ID: 32601266
[TBL] [Abstract][Full Text] [Related]
10. Sustained response of carcinoma ex pleomorphic adenoma treated with trastuzumab and capecitabine.
Sharon E; Kelly RJ; Szabo E
Head Neck Oncol; 2010 May; 2():12. PubMed ID: 20504363
[TBL] [Abstract][Full Text] [Related]
11. Case report: ado-trastuzumab as second-line treatment in HER2 positive salivary duct carcinoma.
Taha T; Billan S
Anticancer Drugs; 2022 Jan; 33(1):e760-e763. PubMed ID: 34387606
[TBL] [Abstract][Full Text] [Related]
12. Combination of docetaxel, trastuzumab and pertuzumab or treatment with trastuzumab-emtansine for metastatic salivary duct carcinoma.
van Boxtel W; Boon E; Weijs WLJ; van den Hoogen FJA; Flucke UE; van Herpen CML
Oral Oncol; 2017 Sep; 72():198-200. PubMed ID: 28673692
[No Abstract] [Full Text] [Related]
13. Benefit of eribulin in a patient with HER2(+) breast cancer who progressed after trastuzumab and lapatinib: a case report.
Casanova C; Verlicchi A; Mazza V; Dazzi C
Future Oncol; 2015; 11(15 Suppl):9-15. PubMed ID: 26235259
[TBL] [Abstract][Full Text] [Related]
14. Health-related quality of life in patients receiving first-line eribulin mesylate with or without trastuzumab for locally recurrent or metastatic breast cancer.
Schwartzberg L; McIntyre K; Wilks S; Puhalla S; O'Shaughnessy J; Berrak E; He Y; Vahdat L
BMC Cancer; 2019 Jun; 19(1):578. PubMed ID: 31195996
[TBL] [Abstract][Full Text] [Related]
15. Abiraterone in metastatic salivary duct carcinoma.
Urban D; Rischin D; Angel C; D'Costa I; Solomon B
J Natl Compr Canc Netw; 2015 Mar; 13(3):288-90. PubMed ID: 25736005
[TBL] [Abstract][Full Text] [Related]
16. A 20-Year Review of 75 Cases of Salivary Duct Carcinoma.
Gilbert MR; Sharma A; Schmitt NC; Johnson JT; Ferris RL; Duvvuri U; Kim S
JAMA Otolaryngol Head Neck Surg; 2016 May; 142(5):489-95. PubMed ID: 26939990
[TBL] [Abstract][Full Text] [Related]
17. Salivary duct carcinoma ex pleomorphic adenoma of the palate: a case report.
Bourell LG; Chan KC; Hirsch DL
J Oral Maxillofac Surg; 2015 Feb; 73(2):370.e1-7. PubMed ID: 25579019
[TBL] [Abstract][Full Text] [Related]
18. Eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: a phase II, multicenter, collaborative, open-label, single-arm clinical trial.
Inoue K; Ninomiya J; Saito T; Okubo K; Nakakuma T; Yamada H; Kimizuka K; Higuchi T;
Invest New Drugs; 2019 Jun; 37(3):538-547. PubMed ID: 30848403
[TBL] [Abstract][Full Text] [Related]
19. Targeted therapy with trastuzumab for advanced salivary ductal carcinoma: case report and literature review.
Kaidar-Person O; Billan S; Kuten A
Med Oncol; 2012 Jun; 29(2):704-6. PubMed ID: 21380780
[TBL] [Abstract][Full Text] [Related]
20. Human epidermal receptor 2-amplified salivary duct carcinoma: regression with dual human epidermal receptor 2 inhibition and anti-vascular endothelial growth factor combination treatment.
Falchook GS; Lippman SM; Bastida CC; Kurzrock R
Head Neck; 2014 Mar; 36(3):E25-7. PubMed ID: 23852769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]